Purpose: A subgroup of human epidermal growth factor receptor 2 (HER2)-overexpressing breast tumors coexpresses p95HER2, a truncated HER2 receptor that retains a highly functional HER2 kinase domain but lacks the extracellular domain and results in intrinsic trastuzumab resistance. We hypothesized that lapatinib, a HER2 tyrosine kinase inhibitor, would be active in these tumors. We have studied the correlation between p95HER2 expression and response to lapatinib, both in preclinical models and in the clinical setting.
The human epidermal growth factor receptor (HER) family of receptors is composed of four closely related tyrosine kinase (TK) receptors: HER1, HER2, HER3, and HER4. All HER receptors consist of an NH 2 terminus extracellular ligand-binding domain, a short transmembrane region, and an intracellular TK domain (1) (2) (3) .
Dimerization of HER receptors, induced by ligand binding or receptor overexpression in the case of HER2, leads to the interaction between the intracellular kinase domain of the receptors and subsequent transphosphorylation of several tyrosine residues located in the COOH-terminal tails (4, 5) . These phosphorylation events trigger the recruitment of several adaptor proteins that mediate the activation of downstream signaling pathways. Among them, the phosphoinositide 3-kinase (PI3K)-Akt-mammalian target of rapamycin and the mitogen activated protein kinases (MAPK) pathways promote cell proliferation, transformation, and survival (6, 7) .
Overexpression/amplification of HER2 occurs in ∼ 20% of human breast cancers and is associated with a more aggressive phenotype and worse prognosis (8, 9) . HER2overexpressing tumors are sensitive to monoclonal antibodies (mAb) and small-molecule TK inhibitors (TKI) that interfere with HER2 function and signaling (10) (11) (12) (13) (14) . Trastuzumab, a humanized mAb directed against the extracellular domain (ECD) of the receptor, was the first approved therapy for the treatment of HER2-positive breast cancer. Trastuzumab in combination with chemotherapy has shown a robust improvement in disease-free and progression-free survival (PFS) in addition to overall survival in the advanced disease (15, 16) as well as in the early (adjuvant) setting (17) (18) (19) .
Despite the considerable clinical benefit provided, a large fraction of HER2-positive tumors display primary or acquired resistance to trastuzumab (for review, see ref. 20 ). Among the potential mechanism of resistance to trastuzumab, the presence of truncated forms of HER2 lacking the trastuzumab-binding ECD [collectively known as p95HER2 or HER2 COOH-terminal fragments (CTF); ref . 14] has been extensively studied.
p95HER2 is expressed in up to 30% of HER2-positive breast cancers and is associated with increased nodal metastasis and shorter disease-free survival when compared with patients that overexpress full-length HER2 (21, 22) . These truncated receptor fragments, produced by either proteolytic shedding of the HER2 receptor ECD (23) or, more frequently, by alternative initiation of translation of the HER2 mRNA (24) , retain kinase activity and promote mammary tumor progression and metastasis even more aggressively than full-length HER2 (25) . Because p95HER2 lacks the extracellular trastuzumab binding domain, we hypothesized that these receptors would not be inhibited by this antibody. This turned out to be the case. We have recently shown that tumor xenografts expressing p95HER2 are refractory to the inhibitory effects of trastuzumab (14, 24) . Importantly there was an association between p95HER2 expression and lack of clinical response to trastuzumab in HER2-amplified breast cancer patients (14) . On the other hand, p95HER2 retains its kinase activity and, we and others, have shown that p95HER2-expressing
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Lapatinib binds to the ATP binding site of both HER1 and HER2, preventing receptor phosphorylation and activation of downstream signaling (14, (28) (29) (30) .
Lapatinib when given in combination with capecitabine significantly improved time to progression in HER2positive breast cancer patients that progressed on trastuzumab-based therapy, compared with capecitabine alone (13) . Moreover, lapatinib as monotherapy and in combination with paclitaxel has clinical activity as first-line treatment in HER2-positive breast cancer patients (31, 32) . Taken together, these observations led to the hypothesis that lapatinib may be active in patients with p95HER2expressing tumors.
To test this hypothesis, we first studied the antitumor activity of lapatinib in two animal models characterized by p95HER2-positive tumors that are either resistant to trastuzumab or depend on p95HER2 to grow. Subsequently, we analyzed the relationship between p95HER2 expression and response to lapatinib in HER2-positive patients who received lapatinib as monotherapy or in combination with capecitabine.
Materials and Methods
Cell lines and animal studies. Four-to 6-week-old BALB/c nu/nu athymic female mice were purchased from the National Cancer Institute Frederick Cancer Center and were maintained in pressurized ventilated caging. All studies were done in compliance with the Institutional Animal Care and Use Committee guidelines.
Fo5 tumors (kindly provided by Gail Lewis Phillips and Mark Sliwkowski: Genentech Inc) were established by s.c. implanting 2 × 2 × 2-mm-sized tumor pieces in the right flanks of the nude mice. Animals with well-established tumors were randomized and treated with 75 mg/kg BID 5× week lapatinib (provided by GlaxoSmithKline).
Tumor xenografts were measured with calipers and tumor volumes were determined using the formula: (length × width 2 ) × (π/6).
MEFs-3T3 tet-off cell lines, engineered to express the tetracycline-controlled transactivator (33), were obtained from Clontech Laboratories. Cells (1 × 10 6 ) stably transfected with the pUHD10-3h vector encoding the cDNA of p95HER2 starting at methionine 611 (611-CTF; ref. 25) were injected into the right flanks of 6-to 8week-old female BALB/c athymic mice purchased from Charles Rivers Laboratories and the expression of 611-CTF was induced by doxycycline removal. Animals with well-established tumors were randomized and treated with 150 mg/kg daily lapatinib or with 10 mg/kg twice weekly trastuzumab (Herceptin; kindly provided by F. Hoffmann-La Roche). Tumor xenografts were measured as described above.
Tumor volumes are plotted as means ± SEM.
Immunoblotting. Tumor lysates were prepared by homogenization in SDS lysis buffer [50 mmol/L Tris-HCl (pH7.4), 2% SDS], boiling for 10 minutes, followed by brief sonication. Lysates were cleared by centrifugation at 14,000 × g for 10 minutes and the supernatants were collected. Protein concentration of each sample was determined using the BCA kit (Pierce) as per the manufacturer's instructions. Fifty micrograms of protein lysate were loaded onto 7% or 10% SDS-PAGE minigels for immunoblotting. Transfer was onto nitrocellulose membranes followed by incubation with the following primary antibodies: PI3K-p85 from Upstate Biotechnology and total HER2 (CB11, Biogenex), phospho-HER2, phospho-Akt (pAkt, S473, and T308), and phospho MAPKs (p-MAPK) from Cell Signaling.
Immunohistochemistry. Xenografts samples were prepared as described earlier (34) . Primary antibody was p-MAPKs from Cell Signaling and secondary anti-rabbit antibody was from Amersham Biosciences. As a negative control, primary antibody was omitted. Slides were scanned with the ScanScope CS system (Aperio). Quantification of p-MAPKs was obtained by scoring two slides each from five different tumors, from both placebo and lapatinib-treated groups, by a qualified pathologist (LP) and displayed as H score plotted as means ± SEM. Patients. Women participating in one of two clinical trials provided written informed consent, allowing for biomarker research to be done on tumor tissue obtained at the time of their diagnosis or at surgery. The details for both trials, including efficacy and safety outcome, have been previously reported (13, 31, 35) . Briefly, in study EGF20009, 138 women with HER2-positive (fluorescence in situ hybridization positive) treatment-naïve, advanced breast cancer randomized in a 1:1 ratio to receive oral lapatinib 1,500 mg once daily or oral lapatinib 500 mg twice daily. In study EGF100151, 399 women with HER2-positive (immunohistochemistry 3+ and/or fluorescence in situ hybridization positive) advanced breast cancer previously treated with anthracycline-, taxane-, and trastuzumab-based therapy were randomized in a 1:1 ratio to receive 2,500 mg/m 2 capecitabine (days 1-14 of a 21-d cycle) or 2,000 mg/m 2 capecitabine (days 1-14 of a 21-d cycle) with 1,250 mg lapatinib once daily (continuously). In both clinical studies, efficacy analyses were conducted based on both investigator and blinded independent central review assessment of tumor response and progression using the Response Criteria in Solid Tumor guidelines (36) in the intent-to-treat patient population.
Immunofluorescence detection of p95HER2 in breast tumors. Patients with sufficient tumor tissue available (i.e., at least two slides per section) and with a clear invasive cellular component were included in the evaluation of p95HER2 expression with the aim of obtaining a more robust estimation of the incidence of p95HER2 expression.
The expression of NH 2 terminally truncated HER2 was evaluated by immunofluorescence as previously described and scored by two pathologists (L.P. and C.A.; ref. 14) . The investigators at our institution, including the pathologists, were blinded to the study or the therapy arm of the analyzed slides.
To increase the stringency of the analyses, tumors were scored positive for p95HER2 expression if ≥50% of tumoral cells showed any cytoplasmic staining detected with the anti-HER2 ICD antibody (recognizing both membrane and cytoplasmic HER2). Cytoplasmic staining was confirmed by colocalization with the anti-cytokeratin antibody, as observed by a yellow (red and green merged) signal (Fig. 1 ). In addition, HER2 ICD staining was compared with the pure membrane staining observed with the anti-HER2 ECD antibody that does not colocalize with cytokeratin staining. All fluorescence assays were done using a DAKO Autostainer.
Fluorescent signals were analyzed with a FluoView FV1000 Olympus Confocal Microscope and evaluated by two independent pathologists (L.P. and C.A.) blinded to clinical information.
Statistical methods. For nude mice experiments, comparisons between groups were made using a two-tailed Student's t test. Differences for which P was <0.05 were considered statistically significant.
Blinded independent central review was the protocoldefined assessment of the primary end point in both studies and thus used in analyses with p95HER2. Overall response rate (ORR; confirmed complete or partial response) and clinical benefit rate (CBR; confirmed complete response or partial response, or stable disease for >6 mo) were compared between p95HER2-positive and p95HER2-negative groups using χ 2 tests. PFS was compared between p95HER2-positive and p95HER2-negative groups using Cox proportional hazards models and Kaplan-Meier analyses. SAS was used for statistical analysis and S-Plus was used for graphical display. In study EGF20009, the data from the two lapatinib monotherapy arms (two dose cohorts) were combined as no significant differences in the clinical outcome parameters were observed and both patient as well as tumor characteristics were balanced (31) .
Results
Lapatinib efficacy in mice bearing trastuzumab-resistant p95HER2-positive breast tumors. We recently showed that MCF-7 cells stably expressing p95HER2 and resistant to trastuzumab remained sensitive to the antiproliferative effects of the TKI lapatinib, both in vitro and in vivo (14) . To expand these results in a model that more closely resembles the situation encountered in the clinic, we tested the growth-inhibitory activity of lapatinib in MMTV-HER2 Fo5 mammary tumor transplants, a trastuzumab-refractory breast tumor that coexpresses, as in clinical specimens, both full-length HER2 and p95HER2 (37) . These cells were isolated from breast tumors derived from the MMTV-HER2 transgenic mouse lineage 5 that spontaneously became insensitive to trastuzumab therapy (38, 39) .
In Fig. 2A , we show that lapatinib (75 mg/kg BID 5× week) markedly reduces tumor growth in mice bearing Fo5 tumors compared with placebo-treated controls. In a pharmacodynamic study, we treated Fo5-bearing mice with five consecutive doses of lapatinib (100 mg/kg BID) and then sacrificed the mice at the indicated times after the final dose (two mice per time point are shown). Immunoblots of lysates of these tumors show that the phosphorylation of p95-HER2 and HER2 is downregulated 3 and 6 hours after the last lapatinib administration (Fig. 2B) . The inhibition of HER2 and p95-HER2 phosphorylation is associated with the downregulation of phosphorylated Akt (S473 and T308) and MAPKs (Fig. 2B ). p85-PI3K blots serve as loading controls. These results are representative of two independent experiments.
Lapatinib activity in targeting p95HER2-dependent tumors. To assess the exquisite activity of lapatinib in inhibiting p95HER2-dependent tumor growth, we used an experimental model based on mouse embryonic fibroblasts (MEF) stably transfected with the most active fragment of p95HER2 (611-CTF), produced by alternative initiation of translation starting at methionine 611 of the HER2 sequence (25) . The expression of this form of p95HER2 is tightly controlled by a tet-off inducible system (see Materials and Methods) and the tumorigenicity of these MEF stable clones stringently depend on the expression/activity of the oncogene. As expected, tumors derived from MEFs expressing 611-CTF were refractory to trastuzumab (10 mg/kg twice weekly, Supplementary Fig. S1 ). Lapatinib treatment (150 mg/kg daily) strongly inhibits the tumor growth of MEFs expressing 611-CTF (Fig. 3A) .
To confirm that the tumorigenesis of these cells is dependent on 611-CTF expression, we switched off 611-CTF expression (by adding doxycycline) in a separate group of animals with a xenograft volume of ≥500 mm 3 . In these mice, doxycycline administration in the drinking water rapidly abolishes 611-CTF expression and, consequently, leads to tumor shrinkage ( Fig. 3B) .
Inhibition of MAPKs phosphorylation is shown ( Fig. 3C  and D) as a readout of lapatinib inhibition of 611-CTF signaling (25) . These results are representative of two independent experiments.
p95HER2 expression in tumor tissue from studies EGF20009 and EGF100151. Tumor tissue was evaluable for p95HER2 analysis in 68 of 138 patients from study EGF20009 and in 156 of 399 patients from study EGF100151. Although we were able to obtain a higher tumor number (105 and 223 for EGF20009 and EGF100151, respectively), not all tumor sections were evaluable. In EGF20009, the first-line lapatinib single-agent study, 20.5% (14 of 68) had tumors that were p95HER2 positive whereas 79.5% (54 of 68) were negative. In EGF100151, the capecitabine plus lapatinib study, 28.5% (45 of 156) tumors were p95HER2 positive and 71.5% (111 of 156) were negative. Overall, 26% of HER2-positive tumors were positive for p95HER2 expression, an incidence consistent with previous reports (14, 21, 22) . In those patients with p95HER2 evaluable results (Table 1) , the patient and disease characteristics were generally a representative of the corresponding study populations as a whole (13, 31) .
Relationship of p95HER2 status with clinical outcome. To determine whether the presence of p95HER2 affected the efficacy of lapatinib in the clinic, PFS was analyzed in lapatinib-treated patients subgrouped according to the p95HER2 status of their tumor. In patients receiving lapatinib as first-line treatment, no statistically significant difference in PFS was observed between the p95HER2positive and p95HER2-negative subgroups [hazard ratio, 1.35; 95% confidence interval (95% CI), 0.64, 2.8; P = 0.417; Fig. 4A ]. Similarly, PFS as a result of lapatinib plus capecitabine treatment was not significantly different between the two p95HER2 subgroups (hazard ratio, 1.30; 95% CI, 0.63-2.69; P = 0.471; Fig. 4B ).
An analysis was conducted to determine whether the presence of p95HER2 had an effect on CBR or ORR as an outcome of lapatinib-based treatment. CBR and ORR were not significantly associated with p95HER2 expression ( Table 2 ). In patients treated with monotherapy lapatinib (EGF20009), the CBR for the p95HER-positive group was 29% (95% CI, 2-56) versus 43% (95% CI, 29-57) for the p95HER2-negative group (P = 0.379). In patients treated with lapatinib plus capecitabine (EGF100151), a CBR of 38% (95% CI, 13-68) versus 40% (95% CI, 25-57) was observed in the p95HER2-positive versus p95HER2negative groups, respectively (P = 0.999). Additionally, ORR was not significantly different between the two p95HER2 subgroups regardless of whether patients were treated with lapatinib alone or in combination with capecitabine (EGF20009: P = 0.7580; EGF100151: P = 0.999). The ORR and CBR in both p95HER2 populations in each trial are consistent with the tumor response rates reported in the respective overall study populations (31, 32) .
Discussion
Resistance to trastuzumab remains a challenge in the therapy of HER2-overexpressing breast cancer and efforts are being directed at identifying potential underlying mechanisms (40) . A potential leading cause of trastuzumab resistance is the coexpression in HER2-amplified tumors of p95HER2, a truncated form of the HER2 receptor that lacks the trastuzumab-binding ECD but retains a functional HER2 kinase domain and is highly tumorigenic (25) . Given the high HER2 kinase activity of p95HER2, a potential approach A, analysis of PFS subgrouped by p95HER2 status in patients treated with lapatinib monotherapy (EGF20009) or (B) with lapatinib in combination with capecitabine (EGF100151). Among patients with HER2-positive tumors exhibiting the coexpression of p95HER2 versus those with HER2-positive tumors that were p95HER2 negative, no significant difference in PFS was observed in either study.
to treat these tumors would be with HER2 receptor TKIs (14, 26) .
In this study, we have that trastuzumab-refractory breast tumors that coexpress, as in clinical specimens, both full-length HER2 and p95HER2 are sensitive to the TKI lapatinib. We also show that tumors coexpressing p95HER2 seem to respond similarly to lapatinib as tumors expressing only the full-length HER2 receptor; this result needs further validation due to the small sample sizes. In clinical samples from two large lapatinib studies in patients with advanced HER2-positive breast cancer, we observed that the presence of p95HER2 occurs in ∼25% of HER2-amplified breast tumors. In these two studies, tumors expressing p95HER2 were sensitive to lapatinib. In fact, both the PFS and CBR in both studies were not statistically different in the p95HER2-positive and p95HER2-negative groups. Taking in consideration that p95HER2 tumors are resistant to trastuzumab (14) , our results suggest that lapatinib, as well as other TKIs, may be a preferred therapeutic option for these tumors.
Hence, the presence of p95HER2 could determine the choice of anti-HER2 therapy if the results are further validated. We are prospectively studying the role of p95HER2 in the neoadjuvant study NeoALTTO as well in the adjuvant study ALTTO as both compare the clinical benefit with trastuzumab versus lapatinib versus the two agents given in combination. In addition, we are planning a prospective clinical trial with lapatinib in patients with tumors selected for p95HER2 expression. There is also a need to develop a user friendly and reproducible method of p95HER2 detection. Immunofluorescence detection of p95HER2, as used here, is complex, time demanding, and requires a confocal microscope, which would limit its widespread implementation. We have recently developed a mAb directed against an epitope uniquely present in p95HER2 and not full-length HER2. The mAb performs well in paraffin-embedded tissues (data not shown) and is in the process of being evaluated in clinical samples. If validated, the presence of p95HER2 could be detected through immunohistochemistry, the same method widely used to detect HER2 overexpression.
There are additional questions that deserve to be explored. At this time, we do not know whether p95HER2 is solely responsible for primary resistance to trastuzumab or if, on the contrary, acquired expression can occur as a result of clonal selection in tumors treated with trastuzumab over prolonged periods of time. If this were the case, upfront therapy with a combination of trastuzumab and lapatinib could potentially delay its appearance. We also do not know if p95HER2 coexists with other potential mechanism of resistance to anti-HER2 therapies such as PI3K mutations or PTEN loss of function.
As with other breast cancer subtypes, there will be an increasing need to further classify HER2 tumors into different subsets that may have different clinical outcomes and benefit from anti-HER2 therapies. Although this will undoubtedly add complexity to our daily clinical practice, it will also result in an improved management of patients with HER2-positive breast cancer and a better choice of therapy. 
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